Abstract

This paper explores the feasibility and principle of hepatic parenteral fluorescence imaging technology after retrograde injection of indocyanine green (ICG) through endoscopic nasobiliary drainage (ENBD). The data were collected from 53 patients with cholecystolithiasis and choledocholithiasis, from October 2022 to March 2023, diagnosed by fluorescence imaging technique retrograde biliary approach (FIT-RB). We divided the patients into two groups according to the features of liver parenchyma, the poor group (n = 34, including scattered or no imaging) and the good group (n = 19, regular uniform imaging). We compared and analyzed the perioperative results of the two groups and explored the influencing factors of the success of FIT-RB and the ICG concentration suitable for this imaging technique. The good imaging rate of the 53 enrolled cases was 35.8%. The bilirubin level before ENBD and laparoscopic cholecystectomy in the poor group was significantly higher than that in the good group (P < 0.001). The proportion of higher ICG concentrations (0.5 mg/mL) was significantly higher in the good group (P = 0.028). Our results demonstrated that the success rate of good imaging was 4.53 times higher than that of low-dose ICG (0.125 or 0.25 mg/L) cases at 0.5 mg/ml of ICG. The level of total bilirubin and direct bilirubin were negatively correlated with the imaging effect, and total bilirubin and direct bilirubin levels were important predictors of the efficacy of FIT-RB. FIT-RB is safe and feasible in patients with low site bilirubin levels. An ICG concentration of 0.5 mg/ml may be ideal for implementing this technique.

Details

Title
Preliminary exploration of hepatic parenchymal near-infrared fluorescence imaging technique via retrograde biliary approach: a feasibility study (with video)
Author
Gao, Fengwei 1 ; Xie, Qingyun 1 ; Zhao, Xin 2 ; Yang, Manyu 3 ; Jiang, Kangyi 4 ; Zhang, Ling 4 ; Mao, Tianyang 3 ; Wu, Hong 1 

 West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Liver Transplantation Center, State Key Laboratory of Biotherapy and Cancer Center, Chengdu, China (GRID:grid.412901.f) (ISNI:0000 0004 1770 1022) 
 The People’s Hospital of Leshan, Department of Hepato-Pancreato-Biliary Surgery, Leshan, China (GRID:grid.412901.f) 
 North Sichuan Medical College, Nanchong, China (GRID:grid.449525.b) (ISNI:0000 0004 1798 4472) 
 The People’s Hospital of Leshan, Department of Hepato-Pancreato-Biliary Surgery, Leshan, China (GRID:grid.449525.b) 
Pages
2380
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2919763571
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.